Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury

Martin Oudega; Owen Y. Chao; Donna L. Avison; Roderick T. Bronson; William J. Buchser; Andres Hurtado; Barbara Grimpe

doi:10.1016/j.expneurol.2012.06.006

Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury

Martin Oudega, Owen Y. Chao, Donna L. Avison, Roderick T. Bronson, William J. Buchser, Andres Hurtado, Barbara Grimpe

School of Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.

Original language	English (US)
Pages (from-to)	170-179
Number of pages	10
Journal	Experimental Neurology
Volume	237
Issue number	1
DOIs	https://doi.org/10.1016/j.expneurol.2012.06.006
State	Published - Sep 2012

Keywords

Chondroitin sulfate proteoglycans
DNA enzyme
Functional recovery
Glial scar
Neurotherapeutics
Regeneration
Spinal cord injury

ASJC Scopus subject areas

Neurology
Developmental Neuroscience

Access to Document

10.1016/j.expneurol.2012.06.006

Cite this

@article{1e7f2df023a54e88b5bddd669c438c49,

title = "Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury",

abstract = "After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.",

keywords = "Chondroitin sulfate proteoglycans, DNA enzyme, Functional recovery, Glial scar, Neurotherapeutics, Regeneration, Spinal cord injury",

author = "Martin Oudega and Chao, {Owen Y.} and Avison, {Donna L.} and Bronson, {Roderick T.} and Buchser, {William J.} and Andres Hurtado and Barbara Grimpe",

note = "Funding Information: We thank the Animal/Behavioral and Histology Core Facilities, Dr. Alex Marcillo, and Dr. Beata Frydel of the Miami Project to Cure Paralysis, and Heidrun Podini and Julia Domke. This work was supported by the Department of Physical Medicine and Rehabilitation at the University of Pittsburgh (MO) ; the German Research Foundation (DFG , BG); Forschungskommission of the HHU (BG); Ralph Wilson Medical Research Foundation (BG); Buoniconti Fund (BG); and the Florida State Fund (BG). The authors declare no conflict of interest.",

year = "2012",

month = sep,

doi = "10.1016/j.expneurol.2012.06.006",

language = "English (US)",

volume = "237",

pages = "170--179",

journal = "Experimental Neurology",

issn = "0014-4886",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury

AU - Oudega, Martin

AU - Chao, Owen Y.

AU - Avison, Donna L.

AU - Bronson, Roderick T.

AU - Buchser, William J.

AU - Hurtado, Andres

AU - Grimpe, Barbara

N1 - Funding Information: We thank the Animal/Behavioral and Histology Core Facilities, Dr. Alex Marcillo, and Dr. Beata Frydel of the Miami Project to Cure Paralysis, and Heidrun Podini and Julia Domke. This work was supported by the Department of Physical Medicine and Rehabilitation at the University of Pittsburgh (MO) ; the German Research Foundation (DFG , BG); Forschungskommission of the HHU (BG); Ralph Wilson Medical Research Foundation (BG); Buoniconti Fund (BG); and the Florida State Fund (BG). The authors declare no conflict of interest.

PY - 2012/9

Y1 - 2012/9

N2 - After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.

AB - After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.

KW - Chondroitin sulfate proteoglycans

KW - DNA enzyme

KW - Functional recovery

KW - Glial scar

KW - Neurotherapeutics

KW - Regeneration

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84863814693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863814693&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2012.06.006

DO - 10.1016/j.expneurol.2012.06.006

M3 - Article

C2 - 22721770

AN - SCOPUS:84863814693

SN - 0014-4886

VL - 237

SP - 170

EP - 179

JO - Experimental Neurology

JF - Experimental Neurology

IS - 1

ER -

Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this